Cargando…

Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma

Sunitinib is a standard molecular-targeted drug used as a first-line treatment for metastatic clear cell renal cell carcinoma (ccRCC); however, resistance to sunitinib has become a major problem in medical practice. Recently, bromodomain containing 4 (BRD4), a member of the bromodomain family protei...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sakaguchi, Takashi, Yoshino, Hirofumi, Sugita, Satoshi, Miyamoto, Kazutaka, Yonemori, Masaya, Osako, Yoichi, Meguro-Horike, Makiko, Horike, Shin-Ichi, Nakagawa, Masayuki, Enokida, Hideki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955408/ https://www.ncbi.nlm.nih.gov/pubmed/29796168 http://dx.doi.org/10.18632/oncotarget.25190

Ejemplares similares

Regulation of ITGA3 by the dual-stranded microRNA-199 family as a potential prognostic marker in bladder cancer
por: Sakaguchi, Takashi, et al.
Publicado: (2018)

Regulation of ITGA3 by the dual-stranded microRNA-199 family as a potential prognostic marker in bladder cancer
por: Sakaguchi, Takashi, et al.
Publicado: (2017)

Potential therapeutic target secretogranin II might cooperate with hypoxia‐inducible factor 1α in sunitinib‐resistant renal cell carcinoma
por: Fukumoto, Wataru, et al.
Publicado: (2023)

Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylation
por: Yoshino, Hirofumi, et al.
Publicado: (2020)

Dual tumor‐suppressors miR‐139‐5p and miR‐139‐3p targeting matrix metalloprotease 11 in bladder cancer
por: Yonemori, Masaya, et al.
Publicado: (2016)

microRNA‐99a‐5p induces cellular senescence in gemcitabine‐resistant bladder cancer by targeting SMARCD1
por: Tamai, Motoki, et al.
Publicado: (2022)

EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer
por: Okamura, Shunsuke, et al.
Publicado: (2021)

microRNA-210-3p depletion by CRISPR/Cas9 promoted tumorigenesis through revival of TWIST1 in renal cell carcinoma
por: Yoshino, Hirofumi, et al.
Publicado: (2017)

Regulation of UHRF1 by dual-strand tumor-suppressor microRNA-145 (miR-145-5p and miR-145-3p): inhibition of bladder cancer cell aggressiveness
por: Matsushita, Ryosuke, et al.
Publicado: (2016)

Targeting NPL4 via drug repositioning using disulfiram for the treatment of clear cell renal cell carcinoma
por: Yoshino, Hirofumi, et al.
Publicado: (2020)

Oncogenic effects of RAB27B through exosome independent function in renal cell carcinoma including sunitinib-resistant
por: Tsuruda, Masafumi, et al.
Publicado: (2020)

Potential new therapy of Rapalink‐1, a new generation mammalian target of rapamycin inhibitor, against sunitinib‐resistant renal cell carcinoma
por: Kuroshima, Kazuki, et al.
Publicado: (2020)

Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein BRD4 inhibitor (+)-JQ1 in cancer cells
por: Sui, Shiyao, et al.
Publicado: (2019)

Affinity Map of Bromodomain Protein 4 (BRD4) Interactions with the Histone H4 Tail and the Small Molecule Inhibitor JQ1
por: Jung, Marie, et al.
Publicado: (2014)

The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation
por: Li, Zichong, et al.
Publicado: (2013)

Topical estrogen application promotes cutaneous wound healing in db/db female mice with type 2 diabetes
por: Mukai, Kanae, et al.
Publicado: (2022)

BET bromodomain inhibitor (JQ1) and tumor angiogenesis
por: Bid, Hemant Kumar, et al.
Publicado: (2016)

BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1
por: Stewart, Helen Jayne Susan, et al.
Publicado: (2013)

Significance of preoperative screening of deep vein thrombosis and its indications for patients undergoing urological surgery
por: Tatarano, Shuichi, et al.
Publicado: (2021)

Metabolism of JQ1, an inhibitor of bromodomain and extra terminal bromodomain proteins, in human and mouse liver microsomes
por: Li, Feng, et al.
Publicado: (2020)

The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition
por: Yao, Weilong, et al.
Publicado: (2015)

Bromodomain inhibitor JQ1 reversibly blocks IFN-γ production
por: Gibbons, Hunter R., et al.
Publicado: (2019)

First report of inherited protein S deficiency caused by paternal PROS1 mosaicism
por: Nagaya, Satomi, et al.
Publicado: (2021)

The BET-bromodomain inhibitor JQ1 mitigates vemurafenib drug resistance in melanoma
por: Zhao, Bei, et al.
Publicado: (2018)

Bromodomain Inhibitor JQ1 Provides Novel Insights and Perspectives in Rhabdomyosarcoma Treatment
por: Marchesi, Irene, et al.
Publicado: (2022)

MUSASHI‐2 confers resistance to third‐generation EGFR‐tyrosine kinase inhibitor osimertinib in lung adenocarcinoma
por: Yiming, Reheman, et al.
Publicado: (2021)

Transcriptional regulation of autophagy and lysosomal function by bromodomain protein BRD4
por: Sakamaki, Jun-Ichi, et al.
Publicado: (2017)

Transcriptome analysis of dominant-negative Brd4 mutants identifies Brd4-specific target genes of small molecule inhibitor JQ1
por: Decker, Tim-Michael, et al.
Publicado: (2017)

Characterization and treatment of gemcitabine‐ and cisplatin‐resistant bladder cancer cells with a pan‐RAS inhibitor
por: Yoshino, Hirofumi, et al.
Publicado: (2023)

The role of microRNAs in bladder cancer
por: Enokida, Hideki, et al.
Publicado: (2016)

BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis
por: Roberts, Thomas C., et al.
Publicado: (2017)

UBE3A-mediated regulation of imprinted genes and epigenome-wide marks in human neurons
por: Lopez, S. Jesse, et al.
Publicado: (2017)

Bromodomain-Containing Protein BRD4 Is Hyperphosphorylated in Mitosis
por: Wang, Ranran, et al.
Publicado: (2020)

The BET/BRD inhibitor JQ1 improves brain plasticity in WT and APP mice
por: Benito, E, et al.
Publicado: (2017)

VDAC1 is regulated by BRD4 and contributes to JQ1 resistance in breast cancer
por: Yang, Guochao, et al.
Publicado: (2019)

Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4
por: Zengerle, Michael, et al.
Publicado: (2015)

Epigenetic Regulation of Aldosterone Synthase Gene by Sodium and Angiotensin II
por: Takeda, Yoshimichi, et al.
Publicado: (2018)

Enhancement of adenovirus infection and adenoviral vector-mediated gene delivery by bromodomain inhibitor JQ1
por: Lv, Baojie, et al.
Publicado: (2018)

Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer
por: Yamamoto, Keisuke, et al.
Publicado: (2016)

The bromodomain inhibitor JQ1+ reduces calcium-sensing receptor activity in pituitary cell lines
por: Lines, Kate E, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_84ac7cb0gqpgkc53r52reaik15